14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
SION vs RAPP: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Rapport Therapeutics, Inc. (RAPP) is the stronger overall head-to-head candidate over Sionna Therapeutics, Inc. (SION) in the Tradestie Institutional Equity Comparison Engine, winning 4–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). SION carries a Unified Composite Score of 45.6/100 (HOLD) at $3.12 (N/M Forward P/E, 0.0% operating margin), whereas RAPP carries 51.4/100 (HOLD) at $24.82 (N/M Forward P/E, -838.1% operating margin).
Technical & Structure Timing Caution: SION is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.9); meanwhile RAPP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 42.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SION vs RAPP. Trailing 12-month operating profitability (SION 0.0% vs RAPP -838.1%) and valuation multiples (SION N/M vs RAPP N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $1.6B market capitalization and -838.1% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ SION vs RAPP Key Questions & Quantitative Answers
As of Nov 16, 2026, Rapport Therapeutics, Inc. (RAPP) is the stronger overall head-to-head candidate over Sionna Therapeutics, Inc. (SION) in the Tradestie Institutional Equity Comparison Engine, winning 4–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). SION carries a Unified Composite Score of 45.6/100 (HOLD) at $3.12 (N/M Forward P/E, 0.0% operating margin), whereas RAPP carries 51.4/100 (HOLD) at $24.82 (N/M Forward P/E, -838.1% operating margin). Technical & Structure Timing Caution: SION is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.9); meanwhile RAPP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 42.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
RAPP leads the Growth & Scale pillar: SION posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with RAPP at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $20M TTM revenue (N/A gross margin, -838.1% operating margin). On trailing 12-month operating scale, SION generates N/A in USD-normalized revenue versus $20M for RAPP. In operating R&D and SG&A reinvestment, SION deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for RAPP.
RAPP screens cheaper on headline valuation multiples. SION trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas RAPP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 74.2x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SION (-39.0% ROE) versus RAPP (-33.3% ROE) capital efficiency.
In options market volatility and institutional positioning, SION carries 87.7% implied volatility (10th %ile, Compressed (<25th %ile)), a 93.27x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.97β · 78% Vol realized risk). By comparison, RAPP carries 91.1% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.91x (Balanced) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.31β · 108% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.